DJ MARKET TALK: UCB Long-Term Pdts Highlighted At R&D Day

09/22/06 - Dow Jones Newswires

0929 GMT [Dow Jones] UCB's (UCB.BT) R&D update Tuesday will highlight the long-term upside potential for key drug Cimzia to treat psoriasis, Epratuzumab for lupus and Keppra follow-on products, Brivaracetam and Selectracetam in epilepsy, says Deutsche Bank. Near-term investor focus will remain on the anticipated FDA approval of Cimzia in Crohn's disease in December '06. Sees limited upside to the current multiple, given that the stock is currently trading at a 29% premium to the sector. Keeps hold recommendation. Shares trade -0.6% at EUR47. (EXB)

 
Contact us in London. +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 
 

(END) Dow Jones Newswires

September 22, 2006 05:29 ET (09:29 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.